12 September 2014
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Director / PDMR shareholding
Exercise of LTIP options:
Dechra Pharmaceuticals PLC announces that on 11 September 2014, the following Director and PDMR exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 7 September 2011 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP).
Both Ian Page and Zoe Goulding have sold sufficient shares (acquired pursuant to the LTIP exercise) in order to fund the resulting tax liability.
Name |
Capacity |
Options Exercised |
Shares Sold |
Sale Price per share
|
Total beneficial shareholding following this announcement |
Percentage of issued share capital |
Ian Page |
Director |
92,811 |
43,753 |
£7.625 |
955,701 |
1.088% |
Zoe Goulding |
PDMR |
12,619 |
5,949 |
£7.625 |
19,561 |
0.022% |
The exercise of the options was subject to the achievement of performance conditions which vested at 100% of the total award.
For further information, please contact:
Zoe Goulding, Company Secretary and Solicitor
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.